ScreenerHero

OCULOcular Therapeutix, Inc.

NAS · US · Healthcare · Biotechnology · ocutx.com
11.08USD-5.54%Mkt Cap: 2.43B $P/E: —

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation techno…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.43B $
Enterprise Value1.92B $
Revenue (TTM)52.05M $
Gross Profit45.38M $
Net Income (TTM)-265.94M $
Revenue/Share0.2430 USD
Last Price11.08 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees325
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS67576A1007
Valuation
P/E (Trailing)—
P/E (Forward)-7.63
PEG—
EV/EBITDA-6.21
EV/Revenue36.81
P/S46.79
P/B4.68
EPS (TTM)-1.32
EPS (Forward)-1.45
52W Range
6.23048% of range16.44
52W High16.44 USD
52W Low6.230 USD
Profitability
Gross Margin87.35%
Oper. Margin-609.34%
EBITDA Margin0.00%
Profit Margin-511.90%
ROE-40.64%
ROA-32.91%
Growth
Revenue Growth0.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-204.88M $
CapEx (TTM)12.01M $
FCF Margin-305.92%
FCF Yield-6.54%
Net Debt-519.26M $
Net Debt/EBITDA1.68
Balance Sheet
Debt/Equity0.12
Current Ratio13.11
Quick Ratio12.79
Book Value/Sh2.368 USD
Cash/Share2.726 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.09 USD
Upside (mean)+144.5%
Target Range18.00 USD – 34.00 USD
$18.00+144.5% to mean$34.00
# Analysts11
Ownership
Shares Out.219.62M
Float184.80M
Insiders0.93%
Institutions95.48%
Short Interest
Short Ratio12.9d
Short % Float14.37%
Short % Out.12.17%
Shares Short26.74M
Short (prev mo.)26.70M
Technical
SMA 509.463 (+17.1%)
SMA 2009.971 (+11.1%)
Beta0.94
S&P 52W Chg18.16%
Avg Vol (30d)2.38M
Avg Vol (10d)3.60M
Technical Indicators
RSI (14)66.5
MACD0.4839
MACD Signal0.1907
MACD Hist.+0.2933
BB Upper11.35 USD
BB Middle9.273 USD
BB Lower7.194 USD
BB Width44.84%
ATR (14)0.5545 USD
Vol Ratio (20d)1.17x